Hemcheck Sweden AB has signed a distributor agreement with Beamed Trading (“Beamed”) regarding the Jordanian and Qatari markets. The agreement entails an initial order like previous similar agreements.
– Beamed is a well-established distributor in the Middle East with presence in several local markets. We believe they can be a good partner for us in Jordan and Qatar and hope that the collaboration will be successful, says Joen Averstad, CEO of Hemcheck.
– We are very pleased to start a collaboration and to sign this agreement with Hemcheck. We believe that the products are innovative and have good market potential, and we look forward to starting the sales efforts, says Ayman Samaha, Managing Director at Beamed.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
Beamed was formed in 2011 in Qatar. Beamed is one of the local leaders in introducing the latest technology in Physiotherapy, Laboratory, Dermatology, Beauty, X-Ray, Veterinary, Cardiology, Nutrition & General Medical Equipment. Beamed represents several larger companies such as Storz Medical and Biotek.
Read more at: https://beamedtrading.com/
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.